Healthcare entity
Every one of those 1 sits in a single category, market-trends. Hope Medicine is most often covered alongside Bayer, which appears in 1 of these 1 story. The 7 average consequence score is above the beat benchmark of 6.6 in the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Hope Medicine is most often covered alongside Bayer, which appears in 1 of these 1 story. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline. We currently track 1 Healthcare story that mention Hope Medicine, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Hope Medicine. Shared-story counts are live from our verified record — not editorial picks.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Source: manilatimes.net · prnewswire.com
Hope Medicine is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
